Manning & Napier Group's PTCT Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 31 shares of PTC Therapeutics, Inc. (PTCT) worth $2,529, representing 0.00% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 3 quarters.
Based on 13F filings, Manning & Napier Group has maintained this position in PTCT for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 17 shares. Largest reduction occurred in Q1 2026, reducing 111 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +17 | Add 121.43% | 31 | $81.58 |
| Q1 2026 | -111 | Reduce 88.80% | 14 | $65.64 |
| Q4 2025 | +125 | New Buy | 125 | $76.19 |
Manning & Napier Group's PTC Therapeutics Investment FAQs
Manning & Napier Group first purchased PTC Therapeutics, Inc. (PTCT) in Q4 2025, acquiring 125 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held PTC Therapeutics, Inc. (PTCT) for 3 quarters since Q4 2025.
Manning & Napier Group's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q4 2025, adding 125 shares worth $9,524.
According to the latest 13F filing for Q2 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 31 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $2,529.
As of the Q2 2026 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in PTC Therapeutics, Inc. (PTCT) was 125 shares, as reported at the end of Q4 2025.